HTDS - Hard to Treat Diseases (PINK)

[shockdragon]

OTTAWA, March 9 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; Welcome to HTDS Medical) announces that Collagenna Skin care Products has entered into an exclusive distribution agreement with Alphaderm Body and Wellness (ALPHADERM GMBH — Body & Wellness) for Switzerland.

Alphaderm Body and Wellness, a small Swiss Company, developed a line of Body Products with focus on cellulite reduction. Alphaderm sells their line in specialized skin care clinics throughout Switzerland. The company's flagship product is the 'Alphaderm Body Former Anti-cellulite Cream'.

Irene Grimm, founder and CEO of Alphaderm Body & Wellness states, said, " We have been looking for a facial skin care line and I heard about the Collagenna Skin Care Line. We tried the products and were very impressed by them. We know that our client base of about 500 clinics will want to carry this line, and it will allow us to build up our business and expand very rapidly. We have several marketing activities planned and we want to officially introduce the line to the Swiss Industry later in April, 2010. Our initial order of last week sold out in 2 days, so we are very excited."

CEO Michael Arnkvarn stated, "It is our plan to expand further into the European Markets. We have a presence in Scandinavia and now Switzerland. We plan to open at least 2 more countries this year, and we expect Alphaderm Body and Wellness to be an integral partner in this expansion."

The company reminds our shareholders and followers to monitor PinkSheets.com Filing Section and also our IR company web site section "NEWS AND FILINGS" TAB. Non-newsworthy events are not press released however posted on these two separate support sites to keep our followers advised of day-to-day events. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link The MinaMar Marketing Helpdesk.

Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas, where amongst other things they continuously spread false rumors, dark propaganda and innuendos in order to manipulate the trading patterns and thwart company plans for their own "quick profits" and self serving needs. The company and its supporters are monitoring these activities and those are promptly being reported on the Exposing Stock Bashers web site. Visit Exposing Stock Bashers and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and other media that provide safe refuge to these individuals and the remedies available to you as an individual investor.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support Section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at Mina Mar Group.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact The MinaMar Marketing Helpdesk

SOURCE Hard to Treat Diseases

[bdogsdad]

Looks like we are getting there. One step at a time but we really need audited financials and the HIRU shares before this really takes off. That's ok, I'll wait.

[shockdragon]

am i seeing thing or has TD remove buying restriction for HTDS?

[bdogsdad]

Nope, I just tried, won't allow buying only able to sell. ****!!!

[shockdragon]

Thanks.......

[bdogsdad]

Sure, I get scott not allowing due to their relationship with nite but TD I don't understand unless they know or suspect something that we don't. They need to do whatever it takes to get the CE off pinks or ST &TD will never allow buy's.

[shockdragon]

Hard to Treat Diseases (HTDS) Acquired Varicella Approval in Guatemala

SHENZHEN, China, March 11 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; Welcome to HTDS Medical) and its subsidiary Mellow Hope announce that the company received Registration Certificate for its MEVAC-Vari vaccine in Guatemala.

This is the first Final Approval for HTDS' Varicella vaccine in South America. In general, doctors regard Varicella, commonly known as chickenpox, as a mild viral illness. However, approx. 1 in 50 cases chickenpox associates with complications such as pneumonia and encephalitis, and both diseases report high mortality rate.

A source close to HTDS said, "Varicella complications can be averted by a simple vaccination, and we are happy that we obtained the Registration Certificate for our Freeze-dried Varicella vaccine (Mevac-Vari) in Guatemala. As it is Mellow Hope's first Final Approval in South America, we see it as an important step and a very good start for our Varicella vaccine on the South American market. South America offers great potential for our affordable vaccines and our representatives continue their work to deliver Mellow Hope's vaccines to the developing world."

In other company news the HTDS management has learned that on line brokerage Scottrade has lifted restrictions for on line buys on HTDS as the oversold issue is being resolved. The company expects other online brokerages to shortly follow similarly.

The company reminds our shareholders and followers to monitor PinkSheets.com Filing Section and also our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/. Non-newsworthy events are not press released however posted on these two separate support sites to keep our followers advised of day-to-day events. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link The MinaMar Marketing Helpdesk.

Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas, where amongst other things they continuously spread false rumors, dark propaganda and innuendos in order to manipulate the trading patterns and thwart company plans for their own "quick profits" and self serving needs. The company and its supporters are monitoring these activities and those are promptly being reported on the Exposing Stock Bashers website. Visit Exposing Stock Bashers and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and other media that provide safe refuge to these individuals and the remedies available to you as an individual investor.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support Section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at Mina Mar Group.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact The MinaMar Marketing Helpdesk

SOURCE Hard to Treat Diseases

Hard to Treat Diseases (HTDS) Acquired Varicella Approval in Guatemala

[bdogsdad]

All that and scott too. Should be a good day tomorrow..

[shockdragon]

SHENZHEN, CHINA, March 15 /PRNewswire-FirstCall/ - Hard to Treat Diseases
(HTDS; Welcome to HTDS Medical) is pleased to announce that the Chilean
government approved two of the company's penem injectables.
Following 18 months of testing and negotiations, Chilean ISP (Ministry of
Health) approved two of HTDS' penem injectables, Meropenem for Injection
(MEINEN) and Imipenem for Injection (IMINEN). HTDS received the registration
certificate for these two medications from the Chilean ISP and the company
prepares to ship its products to this emerging South American market.
Meropenem and Imipenem See link
Laboratory Detection of Imipenem or Meropenem Resistance in Gram-negative Organisms | CDC Infection Control in Healthcare are antibiotics with wide
range of efficiency, treating infections in lungs, heart, blood, bone,
stomach, etc., and offer great market value for the producers and
distributors.
HTDS' CEO Terry Yuan said, "We are happy that we finalized the test stage
for these two products and received the ISP's certificate. The certificate
will strengthen our supply capacity for the market. HTDS - Mellow Hope through
our Chilean agent holds a powerful position on the local injectables market.
Aligning these two facts, we believe that these two antibiotics will succeed
in Chile and bring solid sales numbers to HTDS. Overall, penem injectables
have great market potential globally, and we continue to seek new market and
distribution opportunities around the world." More on penem injectables can be
found by visiting Oxford Journals
The company reminds our shareholders and followers that the company does not
subscribe to the PinkSheets.com Filing Service. Its IR company web site
section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link
http://minamarmarketinggroup.helpserve.com/should be reviewed by its
followers for further updates on this and other business matters.
Non-newsworthy events are not press released however posted on this separate
support sites to keep our followers advised of day-to-day events, and the
company corporate web site. For any matters relating to retail investor
queries or to send us the company directly a message please click on the
"INVESTOR SUPPORT" TAB or this direct link The MinaMar Marketing Helpdesk.
To be included in company's email database for press releases, industry
updates, and non-weekly activity at the company that may or may not be news
released, please subscribe or opt in mailer at Mina Mar Group.
Safe Harbor Statement
Information in this filing may contain statements about future expectations,
plans, prospects or performance of Hard to Treat Diseases, Inc. that
constitute forward-looking statements for purposes of the safe harbor
Provision's under the Private Securities Litigation Reform Act of 1995. The
words or phrases "can be," "expects," "may affect," "believed," "estimate,"
"project," and similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to Treat
Diseases, Inc. is not a guarantee of future performance. None of the
information in this filing constitutes or is intended as an offer to sell
securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s
actual results may differ materially from those anticipated in such
forward-looking statements as a result of various important factors, some of
which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those
discussed in Hard to Treat Diseases, Inc.'s press releases, public filings,
and statements by Hard to Treat Diseases, Inc.'s management, including, but
not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of
its existing capital resources, Hard to Treat Diseases, Inc.'s ability to
raise additional capital to fund future operations, HTDS Corporation's ability
to repay its existing indebtedness, the uncertainties involved in estimating
market opportunities and, in identifying contracts which match Hard to Treat
Diseases, Inc.'s capability to be awarded contracts. All such forward-looking
statements are current only as of the date on which such statements were made.
Hard to Treat Diseases, Inc. does not undertake any obligation to publicly
update any forward-looking statement to reflect events or circumstances after
the date on which any such statement is made or to reflect the occurrence of
unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact
medicalinfo@htdsmedical.com; For any corporate matters, please contact
The MinaMar Marketing Helpdesk
SOURCE Hard to Treat Diseases
For medical and scientific dialogue inquiry only, please contact
medicalinfo@htdsmedical.com; For any corporate matters, please contact
The MinaMar Marketing Helpdesk

[bdogsdad]

This was GREAT news!!!